RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 7, 2009, Pages 1371-1380

  Huynh, Hung ^a   Pierce Chow, K H ^b   Soo, Khee Chee ^a   Toh, Han Chong ^a   Choo, Su Pin ^a   Foo, Kian Fong ^a   Poon, Donald ^a   Ngo, Van Chanh ^a   Tran, Evelyn ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Angiogenesis; Liver cancer; MTOR; Therapy

Indexed keywords

CELL CYCLE PROTEIN; DRUG DERIVATIVE; EVEROLIMUS; MTOR PROTEIN, HUMAN; MTOR PROTEIN, MOUSE; PROTEIN KINASE; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN A;

ANIMAL; APOPTOSIS; ARTICLE; BLOOD; BODY WEIGHT; CELL PROLIFERATION; DRUG SCREENING; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METABOLISM; MICROVASCULATURE; MOUSE; MOUSE MUTANT; PATHOLOGY; PHOSPHORYLATION;

ANIMALS; APOPTOSIS; BODY WEIGHT; CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; CELL PROLIFERATION; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, SCID; MICROVESSELS; PHOSPHORYLATION; PROTEIN KINASES; SIROLIMUS; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MAMMALIA; MUS;

EID: 67651142420     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00364.x     Document Type: Article

References (54)

1. Ferlay J, Parkin DM, Pisani P. Globocan 2002: cancer incidence, mortality and prevalence worldwide. Lyon : IARC Press 2004.
2. Nagasue N, Kohno H, Chang YC, et al. Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann Surg. 1993 217 : 375 84.
3. Yamamoto J, Kosuge T, Takayama T, et al. Recurrence of hepatocellular carcinoma after surgery. Br J Surg. 1996 83 : 1219 22.
4. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist. 2006 11 : 790 800.
5. Gish RG, Porta C, Lazar L, et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol. 2007 25 : 3069 75.
6. Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/ fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005 97 : 1532 8.
7. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006 24 : 4293 300.
8. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 64 : 7099 109.
9. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006 66 : 11851 8.
10. Llovet J, Ricci S, Mazzaferro V. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): results of a Phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol. 2007 25 (18S LBA1.
11. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006 6 : 729 34.
12. Lee JW, Soung YH, Kim SY, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene. 2005 24 : 1477 80.
13. Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene. 2006 25 : 6436 46.
14. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene. 2004 23 : 3151 71.
15. Treins C, Giorgetti-Peraldi S, Murdaca J, et al. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signalling pathway. J Biol Chem. 2002 277 : 27975 81.
16. Semela D, Piguet AC, Kolev M, et al. Vascular remodelling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol. 2007 46 : 840 8.
17. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangio-genesis: involvement of vascular endothelial growth factor. Nat Med. 2002 8 : 128 35.
18. Luan FL, Ding R, Sharma VK, et al. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int. 2003 63 : 917 26.
19. Luan FL, Hojo M, Maluccio M, et al. Rapamycin blocks tumor progression: unlinking immunosuppression from anti-tumor efficacy. Transplantation. 2002 73 : 1565 72.
20. Sahin F, Kannangai R, Adegbola O, et al. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res. 2004 10 : 8421 5.
21. Elsharkawi M, Staib L, Henne-Bruns D, Mayer J. Complete remission of posttrans-plant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil. Transplantation. 2005 79 : 855 7.
22. Stippel DL, Kasper HU, Schleimer K, et al. Successful use of sirolimus in a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation. Transplant Proc. 2005 37 : 2185 7.
23. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002 2 : 489 501.
24. Elit L. CCI-779 Wyeth. Curr Opin Investig Drugs. 2002 3 : 1249 53.
25. Huang S, Houghton PJ. Targeting mTOR signalling for cancer therapy. Curr Opin Pharmacol. 2003 3 : 371 7.
26. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation. 1997 64 : 36 42. (Pubitemid 27327197)
27. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003 349 : 847 58.
28. Beuvink I, O'Relly T, Zumstein-Mecker S, et al. Antitumor activity of RAD001, an orally active rapamycin derivative. Proc Am Assoc Cancer Res. 2001 42 : 1972.
29. Boulay A, Zumstein-Mecker S, Stephan C, et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res. 2004 64 : 252 61.
30. Homicsko K, Lukashev A, Iggo RD. RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer. Cancer Res. 2005 65 : 6882 90.
31. Majewski M, Korecka M, Kossev P, et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA. 2000 97 : 4285 90.
32. Beuvink I, Boulay A, Fumagalli S, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell. 2005 120 : 747 59.
33. Huynh H, Soo KC, Chow PK, et al. Xenografts of human hepatocellular carcinoma: a useful model for testing drugs. Clin Cancer Res. 2006 12 : 4306 14.
34. Nave BT, Ouwens M, Withers DJ, et al. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J. 1999 344 : 427 31.
35. Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol. 2005 23 : 8093 108.
36. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004 18 : 1926 45.
37. Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene. 2006 25 : 3866 84.
38. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003 362 : 1907 17.
39. Huynh H, Nguyen TT, Chow KH, et al. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol. 2003 3 : 19.
40. Lee HS, Huang AM, Huang GT, et al. Hepatocyte growth factor stimulates the growth and activates mitogen-activated protein kinase in human hepatoma cells. J Biomed Sci. 1998 5 : 180 4.
41. Ishida H, Li K, Yi M, Lemon SM. p21-activated kinase 1 is activated through the mammalian target of rapamycin/p70 S6 kinase pathway and regulates the replication of hepatitis C virus in human hepatoma cells. J Biol Chem. 2007 282 : 11836 48.
42. Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 2006 66 : 3351 4.
43. Budhu A, Forgues M, Ye QH, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006 10 : 99 111.
44. Hobson B, Denekamp J. Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br J Cancer. 1984 49 : 405 13.
45. Eberhard A, Kahlert S, Goede V, et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 2000 60 : 1388 93.
46. Barata JT, Cardoso AA, Nadler LM, Boussiotis VA. Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukaemia cells by down-regulating the cyclin-dependent kinase inhibitor p27 (kip1). Blood. 2001 98 : 1524 31.
47. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004 4 : 335 48.
48. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004 10 : 594 601.
49. Noh WC, Mondesire WH, Peng J, et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res. 2004 10 : 1013 23.
50. Guo H, Zhou T, Jiang D, et al. Regulation of hepatitis B virus replication by the phosphatidylinositol 3-kinase-akt signal transduction pathway. J Virol. 2007 81 : 10072 80.
51. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004 4 : 937 47.
52. Sun SY, Rosenberg LM, Wang X, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 2005 65 : 7052 8.
53. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signalling and activates Akt. Cancer Res. 2006 66 : 1500 8.
54. Mohi MG, Boulton C, Gu TL, et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukaemias caused by oncogenic PTKs. Proc Natl Acad Sci USA 2004 101 : 3130 5.